ATP Guest Scientist Seminar



George Poste, D.V.M., Ph.D, D.Sc., F.R.S.

"Diagnostic Biomarkers and the Human Protein–Drug Interaction Network: Implications and Opportunities for Targeted Oncology Therapies"

Thursday, May 1, 2008 12:00 PM Conference Center Auditorium, Building 549

From 1992 to 1999, Dr. George Poste was Chief Science and Technology Officer and President of Research & Development for one of the largest pharmaceutical companies in the world, SmithKline Beecham. In an industry where bringing a single drug to market makes careers, Poste oversaw registration of 31 drug, vaccine and diagnostic products. Dr. George Poste has been the Director of the Biodesign Institute at Arizona State University in Tempe, AZ since May 2003. In 2006 he was awarded the Albert Einstein Award. In addition to his academic post, he serves as Chief Executive of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in health care.

He is a Fellow of the Royal Society, and the U.K. Academy of Medicine, a Distinguished Fellow at the Hoover Institution at Stanford University, and is a member of the Council for Foreign Relations. In the wake of the 9-11 terrorist attacks, Dr. Poste's expertise was tapped extensively to aid national security. He served as chairman of the task force on bioterrorism for the U.S. Department of Defense, and currently serves as a member of the Threat Reduction Advisory Committee for the Defense Threat Reduction Agency.

He also serves as a member of the National Academy Sciences Working Group on Biological Weapons, the Forum on Microbial Threats of the Institute of Medicine Board on Global Health, and the Institute of Medicine Committee on Advances in Technology and Next Generation Biowarfare Threats. He is Non-Executive Chairman of Orchid Biosciences in Princeton and has served on numerous boards, with current appointments on the Board of Directors for both Monsanto and Exelixis.

Please contact Barbara McElroy at **mcelroy@ncifcrf.gov** or **301-846-6075** with inquiries.

